Intra-operative sentinel lymph node identification using a novel receptor-binding agent (technetium-99m 
Introduction
Mediastinal lymph node dissection (MLND) is an effective procedure for complete local control of non-small cell lung cancer (NSCLC), with subsequent improvement in prognosis as well as nodal staging. On the other hand, MLND is not therapeutic and may even be harmful for patients without lymph node metastasis. Nomori et al. showed that approximately 5% of patients with clinical stage I disease can take advantage of MLND [1] . Moreover, an MLND can cause complications such as recurrent laryngeal nerve palsy, chylothorax, arrythmia and other cardiac complications, although their frequency is low [2] . In addition, the procedure can cause potential immunologic effects from the extensive lymphatic ablation, longer operative time and greater amount of total chest tube drainage. Since the world's population is ageing, many thoracic surgeons are now faced with a growing number of patients with resectable lung cancer that have cardiopulmonary dysfunction or extensive comorbidities. Thus, the use of less invasive surgical procedures in these patients and in the elderly must be considered.
A sentinel lymph node (SLN) is defined as the first lymph node within the lymphatic basin reached by lymphatic drainage from a solid tumour and is the most common site of micrometastases [3] . Therefore, when metastasis is not found in an SLN, most likely it will not be present in more distal lymph nodes. Although the benefit of SLN mapping and biopsy remains controversial, it has gained acceptance as a way to avoid the complications of lymph node dissection and has become a standard procedure for breast cancer and melanoma. Recently, SLNs have been identified during surgery for gastrointestinal cancer and lung cancer to reduce lymph node dissection. Especially in the field of lung cancer, Nomori et al. proposed that it is possible to omit MLND by using SLN navigation surgery [4] ; they previously reported that the identification of SLNs is useful for determining the final indications for segmentectomy in patients with clinical T1N0M0 NSCLC [5] .
The basic technique used for SLN mapping involves injecting a tracer around the tumour and then detecting it when it reaches the first drainage lymph node downstream from the tumour. In other words, the method simply entails the use of tracers and their respective detection devices. SLN mapping has been performed previously in patients with lung cancer using isosulfan blue dye and radioisotopes. Isosulfan blue dye is difficult to detect in thoracic lymph nodes due to anthracosis [6] and can cause anaphylactic reactions. Liptay et al. reported that the sensitivity of radioisotope mapping is better than 80% and that only 5% of SLNs are incorrectly identified [7] . Therefore, the radioisotope method of SLN mapping has mostly been used in patients with lung cancer.
Various colloidal radioisotopes (e.g., technetium-99m sulphur colloid [7] , technetium-99m tin colloid [8] and technetium-99m albumin nanocolloid [9] have been traditionally used for SLN mapping in lung cancer. The reason why various colloidal radioisotopes have been tried is to increase the success rate of SLN detection, which depends largely on the colloidal particles used for the study. Particle size and surface characteristics can influence the rate of colloid drainage from the injection site to the lymphatic capillaries and phagocytosis by lymph node macrophages [10, 11] .
Recently, to identify an agent more acutely representing the physiological flow of lymphatic drainage and accumulation at the SLN, receptor-binding agents of smaller molecular size, targeting mannose-binding proteins in the lymph nodes, have been designed. In the previous report, to simplify the synthesis and labelling procedure and to improve the biological properties, we developed a novel mannose receptor-binding agent, technetium-99m human serum albumin (99mTc-MSA), for SLN identification [12] . This study was designed as the first clinical trial to test the reliability and feasibility of SLN identification using this new radioactive agent in patients with stage I NSCLC.
Materials and methods

Patients
Forty-two patients (30 men, 12 women; mean age 63.3 AE 8.9 years) that were candidates for lobectomy with MLND for stage I NSCLC were consecutively enrolled in the study between October 2007 and March 2009 at the Korea University Guro Hospital. Once approved by the Ethics Committee of the Korea University Guro Hospital, written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Each patient underwent thoracic computed tomography (CT) scanning, brain magnetic resonance imaging, bronchoscopy, and positron emission tomography to preoperatively determine staging.
Injection of radioisotope tracer
A total dose of 1 mCi of 99mTc-MSA in 0.2 ml was administered in one shot at the peritumoural region under chest CTor bronchoscopic guidance approximately 3 h before surgery in the CT room. A dynamic whole-body single photon emission computed tomography (SPECT) lymphoscintigraphic image was obtained at 30 min after injection.
Time course after radioisotope injection
Before the beginning of this study, the time course was monitored by lymphoscintigraphy to determine the optimal timing for radioisotope injection before surgery for the first patient. Lymphoscintigraphy was performed at 30 min, and again at 2, 5 and 21 h post-injection.
Intra-operative SLN mapping
The intra-operative procedures for SLN identification were followed based on Dr Nomori et al.'s method [8] . The radioactivity in the lymph nodes was counted before (in vivo) and after (ex vivo) dissection with a hand-held gamma probe (Neo2000, J&J, Cincinnati, OH, USA). The radioactivity count was recorded for a period of 10 s. SLN was defined as any node for which the count was 5 times the radioactivity of the intrathoracic background value for in vivo counting and 5 times the radioactivity of the resected lung tissue with the lowest count for ex vivo counting. Finally, SLNs identified by ex vivo counting were determined to be the true SLNs because in vivo counting could include radioactivity from the primary tumour.
Pathology examination
All harvested lymph nodes, including SLNs, identified during the operation were examined by frozen sections. They were cut into 2 mm slices and ultimately diagnosed by using formalin-fixed and paraffin-embedded sections with haematoxylin and eosin staining.
Statistical analysis
The identification rate was defined as the percentage of patients with detected SLNs among the whole analysed group. The false-negative rate for SLN identification was assessed by the presence of metastatic lymph nodes not identified as SLNs with the labelled SLNs histologically appearing uninvolved. The statistical analysis was carried out using the SPSS software (SPSS for Windows, release 12.0, Chicago, IL, USA).
Results
The patient characteristics are summarized in Table 1 . The size of the primary tumour was a mean of 2.8 AE 1.3 cm (range 0.8-5.2). According to the TNM classification after surgery, the pathological staging was N1 in five patients and N2 in four patients. No complications were observed during the SLN mapping procedure. Fig. 1 shows the time course after radioisotope injection determined by lymphoscintigraphy. From 30 min after injection, the radioisotope had been taken up by the lymph nodes and its detection did not change until 21 h postinjection. Therefore, we decided to inject radioisotope 1-3 h before the operation.
The mean number of dissected lymph nodes per patient was 22.1 AE 11.6 (range 4-57). Among 42 patients, the SLNs could be identified in 40 patients (95.2%). The mean number of SLNs identified was 2.3 AE 1.1 stations (range 1-5) per patient. There was no correlation between the cancer diameter and number of SLNs (r = À0.03, p = 0.83). Table 2 shows the distribution of dissected lymph nodes, SLNs and lymph node metastasis according to the tumour location. For example, in seven patients with a primary tumour in the right upper lobe, the number of harvested lymph nodes per patient was 20.9 AE 12.99, and lymph nodes in stations 4, 7 and 11 were mostly dissected. SLNs were detected at tracheobronchial, hilar and interlobar lymph nodes, and metastasis was found at the interlobar lymph node in one patient. SLNs were detected at the mediastinal lymph node station in 28 out of 40 patients (70.0%), and at the hilar lymph node station in 35 out of 40 patients (87.5%). Five out of 40 patients (12.5%) had SLNs only in the mediastinum, 12 patients (30.0%) had SLNs only in the hilar lymph node station and 23 patients (57.5%) had SLNs in both the mediastinal and hilar lymph node stations. Table 3 shows the SLNs identified in the hilar lymph node stations. In the hilar lymph node station, interlobar lymph nodes were more frequently identified as SLNs (52.5%).
The distribution of mediastinal SLNs is shown in Table 4 . Four out of seven patients (57.1%) with a primary tumour in the right upper lobe had SLNs at the pretracheal or tracheobronchial lymph nodes. Three out of four patients (75.0%) with a primary tumour in the right middle lobe had SLNs in the paratracheal or subcarinal lymph nodes. Six out of nine patients (66.7%) with a primary tumour in the right lower lobe had SLNs in the subcarinal, paraoesophageal or inferior pulmonary ligament lymph nodes. Eight out of nine patients (88.9%) with a primary tumour in the left upper lobe had SLNs in the subaortic or paraaortic lymph nodes, and one of these nine patients (11.1%) had SLNs in the inferior pulmonary ligament that were non-lobe-specific lymph nodes. Eight out of 11 patients (72.7%) with the primary tumour in the left lower lobe had subcarinal, paraoesophageal or inferior pulmonary ligament SLNs, and remaining three (27.3%) had SLNs in the subaortic or paraaortic lymph nodes, which were non-lobe-specific lymph nodes. Ten out of 40 patients (25.0%) had metastases in 11 SLNs. Three out of the 11 SLNs (27.3%) had skip metastases. No false-negative SLNs were detected in any of the 10 patients with N1 or N2 disease (0%). The relationship between in vivo and ex vivo results for mediastinal SLNs showed concurrence in 29 out of 40 patients (72.5%).
Discussion
The most important factor for colloidal agents used for lymphoscintigraphy is the particle size. Smaller colloidal particles result in faster lymphatic drainage from the injection site, thereby enabling faster imaging. However, a particle size smaller than 5 nm is not ideal for lymphoscintigraphy because such particles can be cleared from the injection site through the lymphatic capillaries as well as the blood capillaries [13] . By contrast, a larger particle size, such as technetium-99m tin colloid, could become lodged within the SLNs for a longer period of time than a small particle size, which could lower the false-negative rate [8] . A disadvantage of using colloids with a larger particle size is that their poor migration from the injection site consequently delays lymphatic drainage, which can make nuclear imaging and the surgical procedure very time consuming and reduce the burden to patients and staff [12] . In addition, larger particles are trapped in the interstitial space [14] . Moreover, the SLN identification rate is reported to be lower in patients with chronic obstructive pulmonary disease compared to smaller particle sizes [15] . The preferred particle size of radiocolloids ranges from 5 to 50 nm [13] ; 99mTc-ASC and 99mTc-albumin nanocolloid fall within this range. Although the optimum particle size for the radioisotope tracer for SLN identification in lung cancer patients has not been determined, technetium-99m sulphur colloid [7] , technetium-99m tin colloid [6, 8] and technetium-99m Table 2 The distribution of dissected lymph nodes, sentinel lymph nodes (SLNs), and lymph node metastasis according to the tumour location. reported that no significant differences were found in either the sensitivities or negative predictive values among the colloid solutions of different particle size used in radiolabelling, although smaller particles have shown a tendency to produce better results [9] . To obtain an agent more accurately that represents the physiological flow of lymphatic drainage and accumulation at the SLN, receptor-binding agents of smaller molecular size, targeting mannose-binding proteins in the lymph nodes, have been designed. 99mTc-diethylenetriaminepentaacetic acid (DTPA)-mannosyl-polylysine was the first such agent reported [16] . To improve the biological properties, 99mTc-DTPAmannosyl-dextran was developed. 99mTc-mercaptoacetylglycylglycylglycine (MAG3)-mannosyl-dextran was developed by employing a more stable bifunctional chelating agent for labelling with 99mTc. Among these agents, 99mTc-DTPAmannosyl-dextran has been previously proved to be nontoxic, to have an acceptable biodistribution and to deliver suitable radiation doses by preclinical studies. In our previous report [12] , we synthesised 99mTc-neomannosyl human serum albumin (99mTc-MSA) and tested its feasibility as a lymphoscintigraphic agent. Our postulation was that the molecular diameter of human serum albumin (HSA) (short axis, 6 nm; long axis, 8 nm), determined by X-ray crystallography [17] , represents the smallest size that does not allow direct drainage into the blood pool through the blood capillaries. Thus, its speed of drainage into the lymphatic system was expected to be maximal, enabling fast imaging of the SLNs. In addition, there are also advantages for the synthesis of the end product; mannose can easily be conjugated with the amino groups of lysine residues in HSA without the use of a linker molecule, and 99mTc can be linked to the HSA protein after reducing the intramolecular disulphide bonds.
Based on the time course monitored by lymphoscintigraphy in this study, 99mTc-MSA could be injected just before surgery or during the operation, which could save time for the surgical procedure and reduce the burden to patients and staff. The SLN identification rate using radioisotopes has been reported as 60-96.1% in patients with NSCLC [6] [7] [8] 15, 18, 19] . The studies using small colloidal particles such as phytate [15] and nanocolloid [18, 19] showed relatively higher rates of SLN detection than the studies using larger particles, which was similar to the results of the present study (95.2%). The false-negative rate was 0% in the study using small colloidal particles [15, 19] , which was also similar to our study. The mean number of SLNs identified was 2.3 AE 1.1 stations (range 1-5) per patient in this study. This number was larger than reported previously (1.76 and 2.08) in which tin colloid was used. There was a comparative study of SLN detection between the two different particle sizes [15] . That report showed that phytate (200-400 nm in diameter) provided an advantage in SLN; it can be detected more frequently than tin colloid because of its small particle size, thereby increasing the number of SLNs per patient (1.7 in the tin colloid group vs 2.4 in the phytate group) and the SLN identification rate, similar to the results of this study. Therefore, small colloidal particles such as phytate, nanocolloid and 99mTc-MSA could easily reach SLNs and continue to flow further up the chain of lymph nodes, thereby increasing the number of SLNs and the SLN identification rate.
In mediastinal lymph node stations, SLNs were detected in 28 out of 40 patients (70.0%). Nomori et al. [8] reported that the SLN for each mediastinal lymph node station was lobe specific in all patients; they showed that lymphatic flow from the right upper lobe proceeds to the pretracheal or tracheobronchial lymph nodes, the left upper lobe to the aortic nodes and the lower lobe to the subcarinal nodes [20, 21] . However, the SLN was not lobe specific in 4 out of 28 patients (14.3%) in this study. One patient with left upper lobe cancer had an SLN in no. 9, and three patients with left lower lobe cancer had SLNs among the aortic lymph nodes. Several reports have shown that there is no definite path for lymphatic spread in relation to the location of the cancer. For example, the study by Hata et al. revealed that the main lymphatic flow from the right upper lobe is to the ipsilateral and contralateral nodes of the upper mediastinum and to the subcarinal group [22] . In addition, Schirren et al. [23] reported that in the right upper lobe, the subcarinal and paraoesophageal and ligamentum pulmonale nodes are involved. The 99mTc-MSA might flow through lymphatic vessels more easily and therefore arrive at SLNs even in nonlobe-specific lymph nodes because of the small particle size. However, the number of SLNs was similar to phytate material despite phytate's larger size. This appears to be due to the fact that 99mTc-MSA appears to stick to SLNs due to its receptor-binding properties. Another possibility might be an incomplete fissure between the lobes; any sized particle might go up to non-lobe-specific lymph nodes. However, this [20, 21, 24] , which could be attributed to lymphatic flow from the lungs going directly to the mediastinum through the pleura and not to hilar lymph node stations [24] . In this study, 5 out of 40 patients (12.5%) had SLNs detected only in mediastinal lymph nodes without hilar lymph node involvement. The skip lymphatic flow to each mediastinal lymph node station was lobe specific in four out of five patients (80.0%), and metastasis was found in two out of four patients. The skip lymphatic flow to each mediastinal lymph node station was non-lobe-specific in one out of five patients (20%), though metastasis was not found in the patient. Finally, 3 out of 11 SLNs (27.3%) with skip metastases were lobe-specific; one patient with right middle lobe cancer had metastasis in no. 7, and two patients with left upper lobe cancer had metastasis among the aortic lymph nodes. These results are supported by previous reports, which showed a similar distribution of prevalence of mediastinal lymph node metastases from each lobe [20, 21, 24, 25] .
To be of practical use for SLN navigation surgery, the in vivo counting data must be accurate. The correlation between in vivo and ex vivo counting for mediastinal lymph node stations showed a 72.5% concurrence, which was lower than that reported by Nomori et al. [8] Therefore, SLN identification using 99mTc-MSA by in vivo counting of mediastinal lymph node stations might not be a useful approach to guide mediastinal lymph node sampling or dissection.
Conclusion
SLN identification using 99mTc-MSA appears to provide excellent results for identification and false-negative rates. In addition, 99mTc-MSA has the advantage of being simple and easy to use. Therefore, 99mTc-MSA is a promising method for SLN identification in patients with stage I NSCLC.
Regarding the first point, the radiotracer, you focused on this new radiotracer, which seems to have one major advantage over the more frequently used tracer, such as nanocolloid, and this is the quick drainage into the lymphatic system, thanks to the size of the particles and the receptorbinding properties in the lymph nodes. So thanks to these properties, this radiotracer could be administered during the procedure. So, Dr Kim, why did you administer the radiotracer 3 h prior to surgery by using CTscan and by using bronchoscopic guidance?
The second point is, sentinel lymph node mapping was initially developed, especially in breast cancer and melanoma and other solid tumours, as a minimally invasive surgical alternative to elective complete lymphadenectomy. However, when we talk about lung cancer, we know that lymphadenectomy still remains the gold standard for lung cancer staging. Probably in the near future this will soon be clarified by the ongoing trials, such as the American College of Surgeons Oncology Group; however, so far the gold standard is lymphadenectomy. So, Dr Kim, was the aim of your study in this field to avoid a complete lymphadenectomy or was it a way to enable pathologists to identify micrometastasis with higher sensitivity analysis in detected sentinel lymph nodes?
Dr Kim: We inject the radioisotope 3 h before surgery. With all the other radioisotopes, such as tin colloid, the molecular size is very big, so the injection of the radioisotope should be administered one day before the surgery, but this molecule is very small, so we can inject the radioisotope just before surgery or during the surgery. So this is a very useful technique for the patient because it is not time consuming.
In answer to the second question, we have tried to evolve our technique to apply to early stage lung cancers, and also the technique of the micrometastasis detection should be followed, but finally, I think that in the end, we can apply this technique with surgery in all patients.
